Shattuck Labs, Inc.

STTK ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $1.0M $5.7M $1.7M $652.0K $30.0M $9.9M $9.9M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $35.3M $67.2M $74.3M $82.9M $56.6M $37.5M $29.2M
SG&A Expense $17.2M $19.1M $19.3M $21.1M $18.7M $9.4M $5.7M
Operating Income $-51.5M $-80.6M $-92.0M $-103.3M $-45.3M $-36.9M $-25.1M
Operating Margin -5,150.8% -1,408.3% -5,549.6% -15,848.0% -150.8% -371.8% -253.5%
Interest Expense
Pretax Income
Income Tax Expense $0 $0 $0 $0 $0 $0 $0
Net Income $-48.8M $-75.4M $-87.3M $-101.9M $-45.0M $-36.6M $-24.0M
Net Margin -4,880.9% -1,318.1% -5,268.4% -15,635.7% -149.8% -368.5% -242.6%
EPS (Basic) $-0.70 $-1.49 $-2.05 $-2.41 $-1.07 $-0.79 $-1.06
EPS (Diluted) $-0.70 $-1.49 $-2.05 $-2.41 $-1.07 $-0.79 $-1.06
Shares Outstanding (Basic) 69.6M 50.8M 42.6M 42.4M 42.0M 46.5M 22.8M
Shares Outstanding (Diluted) 69.6M 50.8M 42.6M 42.4M 42.0M 46.5M 22.8M
Dividends Per Share